Over the past year, Eli Lilly (NYSE: LLY) has impressed investors on almost every front. Financial results have been excellent, clinical progress has been solid, and its stock has crushed the broader market.

If there is one area where Eli Lilly hasn't been close to perfect, though, it's with its planned regulatory goals. Last year, it failed to earn anticipated approval for some new products due to regulatory roadblocks.

Eli Lilly recently ran into another regulatory hurdle that's worth paying attention to as well. What is it and what could it mean for investors?

Continue reading

Source Fool.com